COSCIENS Biopharma Inc. (CSCIF) Form 6-K — May 12, 2026
COSCIENS Biopharma reported a consolidated net income of $10.8 million for the first quarter of 2026, a significant turnaround from the prior year's loss, primarily driven by a $10.9 million gain recognized upon the deconsolidation of its German subsidiaries. The company held $5.0 million in cash and saw total revenue increase to $1.9 million, while operating expenses decreased to $1.5 million due to lower administrative and R&D costs. During the quarter, the company ceased funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, which subsequently filed for insolvency in late March.
Key figures
- Eps
- $3.42
- Revenue
- $1.9 million
- Net Income
- $10.8 million
- Cash Position
- $5.0 million
- Operating Expenses
- $1.5 million
- Income From Continuing Operations
- -$0.2 million
- Income From Discontinued Operations
- $10.9 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.